Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

EIGR

Eiger BioPharmaceuticals (EIGR)

Eiger BioPharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:EIGR
DateTimeSourceHeadlineSymbolCompany
04/01/202411:12AMGlobeNewswire Inc.Eiger BioPharmaceuticals Files for Voluntary Chapter 11 ProtectionNASDAQ:EIGREiger BioPharmaceuticals Inc
03/11/20244:03PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:EIGREiger BioPharmaceuticals Inc
01/24/20244:59PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:EIGREiger BioPharmaceuticals Inc
01/18/20245:49PMPR Newswire (US)Eiger and Partner, AnGes, Receive Approval for ZokinvyĀ® (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in JapanNASDAQ:EIGREiger BioPharmaceuticals Inc
01/08/20247:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:EIGREiger BioPharmaceuticals Inc
01/04/20248:45AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:EIGREiger BioPharmaceuticals Inc
01/04/20248:00AMPR Newswire (US)Eiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse Stock SplitNASDAQ:EIGREiger BioPharmaceuticals Inc
12/11/20234:01PMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:EIGREiger BioPharmaceuticals Inc
12/04/20236:01AMEdgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:EIGREiger BioPharmaceuticals Inc
12/01/20234:02PMEdgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:EIGREiger BioPharmaceuticals Inc
11/24/20236:01AMEdgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:EIGREiger BioPharmaceuticals Inc
11/13/20234:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:EIGREiger BioPharmaceuticals Inc
11/09/20234:27PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EIGREiger BioPharmaceuticals Inc
11/09/20234:14PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:EIGREiger BioPharmaceuticals Inc
11/09/20234:05PMPR Newswire (US)Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:EIGREiger BioPharmaceuticals Inc
11/02/20239:54PMEdgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:EIGREiger BioPharmaceuticals Inc
11/02/20239:14PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EIGREiger BioPharmaceuticals Inc
10/30/20234:51PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:EIGREiger BioPharmaceuticals Inc
10/20/20234:29PMEdgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:EIGREiger BioPharmaceuticals Inc
09/28/20234:54PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:EIGREiger BioPharmaceuticals Inc
09/12/20235:17PMDow Jones NewsEiger BioPharmaceuticals to Discontinue Chronic Hepatitis Delta Study, Ends Licensing TalksNASDAQ:EIGREiger BioPharmaceuticals Inc
09/12/20234:42PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:EIGREiger BioPharmaceuticals Inc
09/12/20234:05PMPR Newswire (US)Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis DeltaNASDAQ:EIGREiger BioPharmaceuticals Inc
09/05/20239:38PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EIGREiger BioPharmaceuticals Inc
09/05/20239:35PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:EIGREiger BioPharmaceuticals Inc
09/05/20234:05PMPR Newswire (US)Eiger BioPharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:EIGREiger BioPharmaceuticals Inc
08/15/20236:00AMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:EIGREiger BioPharmaceuticals Inc
08/14/20234:24PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EIGREiger BioPharmaceuticals Inc
08/14/20234:09PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:EIGREiger BioPharmaceuticals Inc
08/14/20234:05PMPR Newswire (US)Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:EIGREiger BioPharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:EIGR